Platelets

drug
On this page

Also known as Homo sapiens plateletallogenicHuman plateletPlatelets allogenicPlatelets human allogenic

Summary

Platelets (CHEMBL2108632) is a phase-3 clinical-stage unknown; indicated across 10 conditions including injury and palmar fibromatosis.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Unknown
  • Indications: 10 conditions
  • Clinical trials: 21

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2108632
NamePlatelets
TypeUnknown
Max phase3

Also known as: Homo sapiens platelet, allogenic, Human platelet, Platelets, Platelets allogenic, Platelets human allogenic, PLATELETS

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
injury3MONDO:0021178EFO:0000546
palmar fibromatosis2MONDO:0006345EFO:0004229
thrombocytopenia2MONDO:0002049HP:0001873
stroke disorder2MONDO:0005098EFO:0000712
brain injury2MONDO:0043510MONDO:0043510
osteoarthritis, knee2MONDO:0005416EFO:0004616
osteoarthritis1MONDO:0005178MONDO:0005178

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 21.

Phase distribution

PhaseTrials
Not specified14
PHASE33
PHASE22
PHASE41
PHASE2/PHASE31

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06613425PHASE4RECRUITINGClinical Study of Combined Platelet Transfusion
NCT03991481PHASE3ACTIVE_NOT_RECRUITINGThe Cryopreserved vs. Liquid Platelets Trial
NCT04704869PHASE3COMPLETEDEarly Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation
NCT04709705PHASE2/PHASE3COMPLETEDDMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS)
NCT05502809PHASE3UNKNOWNFrozen Platelets in the Treatmentof Traumatic or Vascular Bleeding
NCT01135862PHASE2UNKNOWNPlatelet Administration To Patients With Traumatic Brain Injury Who Were Treated With Aspirin
NCT01283321PHASE2TERMINATEDRiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery
NCT04201704Not specifiedRECRUITINGEffect of Giving Reduced Fluid in Children After Trauma
NCT05713734Not specifiedRECRUITINGBleeding of Unknown Cause: a Swiss Case-control Study
NCT06601894Not specifiedNOT_YET_RECRUITINGThe Relationship of Platelet Counts With Sickle Cell Anemia in the Eastern Region of Saudi Arabia
NCT06623084Not specifiedNOT_YET_RECRUITINGIntegrated Phenotyping of the Gut-plAtelet-Liver AXIS in the Progression of Chronic Liver Disease (iGAL-AXIS)
NCT00537784Not specifiedCOMPLETEDPlatelet Concentrate in Achilles Tendon Repair
NCT00699621Not specifiedUNKNOWNPlatelet Transfusion in Acute Intracerebral Hemorrhage
NCT01534117Not specifiedCOMPLETEDPlatelet Function Analysis in Head Trauma: ASA/Plavix
NCT01810276Not specifiedTERMINATEDSafety of Platelet Transfusion in Patients on Antiplatelet Therapy With Traumatic Head Injury
NCT02305732Not specifiedCOMPLETEDA Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components
NCT02689232Not specifiedCOMPLETEDTEG (Thromboelastography) Based Versus Conventional Coagulation Parameters Based Correction of Coagulopathy in Non Variceal Bleed.
NCT02721940Not specifiedUNKNOWNMononuclear Cells, Platelets and Zoledronic Acid for Preventing Collapse of the Femoral Head in Osteonecrosis
NCT02906878Not specifiedUNKNOWNPlatelet Kinetics After Platelet Transfusion for the Placement of a Central Venous Catheter
NCT03784794Not specifiedCOMPLETEDPatient Blood Management for Massive Obstetric Hemorrhage
NCT06043050Not specifiedCOMPLETEDPRedicting OutcomeS in Preterm nEonates With thromboCyTopenia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).